Patents by Inventor Charles R. Allerson

Charles R. Allerson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Galnac conjugated modified oligonucleotides as miR-122 inhibitor having HCV antiviral activity with reduced hyperbilirubinemia side-effect
    Patent number: 12005120
    Abstract: Described herein are compositions and methods for the inhibition of miR-122 activity. The compositions have certain nucleoside modifications that yield potent inhibitors of miR-122 activity and comprise moieties that facilitate delivery to the liver. The compositions may be administered to subjects infected with hepatitis C virus, as a treatment for hepatitis C virus and related conditions.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: June 11, 2024
    Assignee: Regulus Therapeutics Inc.
    Inventors: Charles R. Allerson, Steven S. Neben, Timothy Wright
  • METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
    Publication number: 20240141350
    Abstract: Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
    Type: Application
    Filed: November 30, 2023
    Publication date: May 2, 2024
    Applicants: Regulus Therapeutics Inc., The Board of Regents of The University of Texas System
    Inventors: Charles R. ALLERSON, Vishal D. PATEL, B. Nelson CHAU, John R. ANDROSAVICH
  • Compositions for treatment of polycystic kidney disease
    Publication number: 20230109466
    Abstract: Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
    Type: Application
    Filed: July 25, 2022
    Publication date: April 6, 2023
    Applicant: Regulus Therapeutics Inc.
    Inventor: Charles R. Allerson
  • METHODS AND COMPOSITIONS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
    Publication number: 20220380767
    Abstract: Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
    Type: Application
    Filed: July 22, 2022
    Publication date: December 1, 2022
    Applicants: Regulus Therapeutics Inc., The Board of Regents of The University of Texas System
    Inventors: Charles R. ALLERSON, Vishal D. PATEL, B. Nelson CHAU, John R. ANDROSAVICH
  • METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
    Publication number: 20220213483
    Abstract: Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
    Type: Application
    Filed: March 21, 2022
    Publication date: July 7, 2022
    Applicants: Regulus Therapeutics Inc., The Board of Regents of The University of Texas System
    Inventors: Charles R. ALLERSON, Vishal D. PATEL, B. Nelson CHAU, John R. ANDROSAVICH
  • MicroRNA Compounds and Methods for Modulating MIR-10B Activity
    Publication number: 20220096517
    Abstract: Described herein are compositions and methods for the inhibition of miR-10b activity. The compositions may be administered to subjects with cancer, such as glioma.
    Type: Application
    Filed: November 12, 2019
    Publication date: March 31, 2022
    Applicant: Regulus Therapeutics Inc.
    Inventor: Charles R. Allerson
  • Galnac Conjugated Modified Oligonucleotides as MIR-122 Inhibitor Having HCV Antiviral Activity with Reduced Hyperbilirubinemia Side-Effect
    Publication number: 20210170034
    Abstract: Described herein are compositions and methods for the inhibition of miR-122 activity. The compositions have certain nucleoside modifications that yield potent inhibitors of miR-122 activity and comprise moieties that facilitate delivery to the liver. The compositions may be administered to subjects infected with hepatitis C virus, as a treatment for hepatitis C virus and related conditions.
    Type: Application
    Filed: May 7, 2019
    Publication date: June 10, 2021
    Applicant: Regulus Therapeutics Inc.
    Inventors: Charles R. Allerson, Steven S. Neben, Timothy Wright
  • Modified Oligonucleotides for Treatment of Polycystic Kidney Disease
    Publication number: 20210095282
    Abstract: Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
    Type: Application
    Filed: September 25, 2020
    Publication date: April 1, 2021
    Applicant: Regulus Therapeutics Inc.
    Inventor: Charles R. Allerson
  • METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
    Publication number: 20200392501
    Abstract: Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
    Type: Application
    Filed: August 27, 2020
    Publication date: December 17, 2020
    Applicants: Regulus Therapeutics Inc., The Board of Regents of the University of Texas System
    Inventors: Charles R. ALLERSON, Vishal D. PATEL, B. Nelson CHAU, John R. ANDROSAVICH
  • METHODS AND COMPOSITIONS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
    Publication number: 20200392503
    Abstract: Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
    Type: Application
    Filed: August 27, 2020
    Publication date: December 17, 2020
    Applicants: Regulus Therapeutics Inc., The Board of Regents of the University of Texas System
    Inventors: Charles R. ALLERSON, Vishal D. PATEL, B. Nelson CHAU, John R. ANDROSAVICH
  • Modified Oligonucleotides for Treatment of Polycystic Kidney Disease
    Publication number: 20200165606
    Abstract: Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
    Type: Application
    Filed: December 4, 2017
    Publication date: May 28, 2020
    Applicant: Regulus Therapeutics, Inc.
    Inventor: Charles R. Allerson
  • METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
    Publication number: 20190345494
    Abstract: Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
    Type: Application
    Filed: December 4, 2017
    Publication date: November 14, 2019
    Inventors: Charles R. ALLERSON, Vishal D. PATEL, B. Nelson CHAU, John R. ANDROSAVICH
  • Fluorescence-based genotyping
    Patent number: 6855500
    Abstract: The present invention relates to a method for genotyping a diploid organism to detect single nucleotide polymorphisms (SNPs) using modified nucleotides or nucleotide residues substituted with fluorescent groups.
    Type: Grant
    Filed: March 26, 2002
    Date of Patent: February 15, 2005
    Assignee: Sequenom, Inc.
    Inventors: Jia Liu Wolfe, Tomohiko Kawate, Charles R. Allerson, Vincent P. Stanton, Jr.
  • Fluorescence-based genotyping
    Publication number: 20030165880
    Abstract: The present invention relates to a method for genotyping a diploid organism to detect single nucleotide polymorphisms (SNPs) using modified nucleotides or nucleotide residues substituted with fluorescent groups.
    Type: Application
    Filed: March 26, 2002
    Publication date: September 4, 2003
    Inventors: Jia Liu Wolfe, Tomohiko Kawate, Charles R. Allerson, Vincent P. Stanton